WntResearch today announces that an application regarding permission to start the Foxy-5 clinical phase 1b study has been submitted to the Danish Health Authorities. 

Nils Brünner, CEO: “This is a very important milestone for WntResearch. I feel confident that the phase 1b study will provide us with the information needed to optimize conditions for the pivotal clinical phase 2 study. The major difference between the phase 1 and 1b studies and the phase 2 study lies in the recruitment of patients. The phase 1 and 1b studies recruit patients who already have metastatic disease and for whom the treating oncologist has no more routine systemic treatment to offer. On the contrary, the phase 2 study will recruit only newly operated cancer patients with no signs of persistent metastatic lesions. Thus, the phase 2 study will give us the final answer to the anti-metastatic efficacy of Foxy-5.”

For additional information please contact:
Nils Brünner, CEO
E-mail: nbr@wntresearch.com
Telephone: + 45 2614 4708

About WntResearch
WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.